Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
256 questions in 49 reviews · Haematology
current versionsNo studies 256 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Intervention NR Number of participants with any bleeding ‐ not reported · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without… Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies… (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Serious infections ‐ not reported · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without… Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies… (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Length of hospital admission ‐ not reported · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without… Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies… (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Hospital readmission rate ‐ not reported · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without… Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies… (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Quality of life ‐ not reported · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without… Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies… (2024) · Cochrane | no estimate extracted | NR | No studies |
Anti‐CD52 mAb maintenance therapy vs observation Overall survival – not reported · people with chronic lymphocytic leukaemia Maintenance therapy for chronic lymphocytic leukaemia (2024) · Cochrane | no estimate extracted | NR | No studies |
Anti‐CD52 mAb maintenance therapy vs observation Health‐related quality of life – not reported · people with chronic lymphocytic leukaemia Maintenance therapy for chronic lymphocytic leukaemia (2024) · Cochrane | no estimate extracted | NR | No studies |
Anti‐CD52 mAb maintenance therapy vs observation Grade 3/4 adverse events – not reported · people with chronic lymphocytic leukaemia Maintenance therapy for chronic lymphocytic leukaemia (2024) · Cochrane | no estimate extracted | NR | No studies |
Anti‐CD52 mAb maintenance therapy vs observation Treatment‐related mortality – not reported · people with chronic lymphocytic leukaemia Maintenance therapy for chronic lymphocytic leukaemia (2024) · Cochrane | no estimate extracted | NR | No studies |
Anti‐CD52 mAb maintenance therapy vs observation Treatment discontinuation – not reported · people with chronic lymphocytic leukaemia Maintenance therapy for chronic lymphocytic leukaemia (2024) · Cochrane | no estimate extracted | NR | No studies |
Anti‐CD52 mAb maintenance therapy vs observation All adverse events – not reported · people with chronic lymphocytic leukaemia Maintenance therapy for chronic lymphocytic leukaemia (2024) · Cochrane | no estimate extracted | NR | No studies |
Immunomodulatory drug maintenance therapy vs placebo/observation Health‐related quality of life – not reported · people with chronic lymphocytic leukaemia Maintenance therapy for chronic lymphocytic leukaemia (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Convalescent plasma vs standard plasma Quality of life, · individuals with moderate to severe disease Convalescent plasma for people with COVID‐19: a living systematic review (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Convalescent plasma vs human immunoglobulin Clinical worsening: need for invasive mechanical ventilation, or death at up to day 28 ‐ not reported · individuals with moderate to severe disease Convalescent plasma for people with COVID‐19: a living systematic review (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Convalescent plasma vs human immunoglobulin Clinical improvement: participants discharged from hospital ‐ not reported · individuals with moderate to severe disease Convalescent plasma for people with COVID‐19: a living systematic review (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Convalescent plasma vs human immunoglobulin Quality of life ‐ not reported · individuals with moderate to severe disease Convalescent plasma for people with COVID‐19: a living systematic review (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Convalescent plasma vs human immunoglobulin Grades 3 and 4 adverse events ‐ not reported · individuals with moderate to severe disease Convalescent plasma for people with COVID‐19: a living systematic review (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Convalescent plasma vs human immunoglobulin Serious adverse events ‐ not reported · individuals with moderate to severe disease Convalescent plasma for people with COVID‐19: a living systematic review (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Convalescent plasma vs placebo or standard care alone Symptom resolution‐ all initial symptoms resolved ‐ not reported · outpatients withmild disease Convalescent plasma for people with COVID‐19: a living systematic review (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Convalescent plasma vs placebo or standard care alone Quality of life, · outpatients withmild disease Convalescent plasma for people with COVID‐19: a living systematic review (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Convalescent plasma vs standard plasma Time to symptom resolution ‐ not reported · outpatients withmild disease Convalescent plasma for people with COVID‐19: a living systematic review (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Convalescent plasma vs standard plasma Quality of life, · outpatients withmild disease Convalescent plasma for people with COVID‐19: a living systematic review (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Convalescent plasma vs standard plasma Grades 3 and 4 adverse events ‐ not reported · outpatients withmild disease Convalescent plasma for people with COVID‐19: a living systematic review (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Convalescent plasma vs standard plasma Serious adverse events ‐ not reported · outpatients withmild disease Convalescent plasma for people with COVID‐19: a living systematic review (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Convalescent plasma vs standard plasma Clinical improvement: participants discharged from hospital ‐ not reported · individuals with moderate to severe disease Convalescent plasma for people with COVID‐19: a living systematic review (2023) · Cochrane | no estimate extracted | NR | No studies |
Remdesivir and standard care vs standard care (plus/minus placebo) Quality of life · non‐hospitalised adults with mild COVID‐19 Remdesivir for the treatment of COVID‐19 (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Quality of life up to longest · non‐hospitalised adults with mild COVID‐19 Antiplatelet agents for the treatment of adults with COVID‐19 (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Adverse events during study treatment · non‐hospitalised adults with mild COVID‐19 Antiplatelet agents for the treatment of adults with COVID‐19 (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Adverse events during study treatment · hospitalised adults with COVID‐19 (moderate to severe disease) Antiplatelet agents for the treatment of adults with COVID‐19 (2023) · Cochrane | no estimate extracted | NR | No studies |
RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies (EpAbs) vs saline placebo Quality of life · individuals with moderate or severe COVID‐19 Hyperimmune immunoglobulin for people with COVID‐19 (2023) · Cochrane | no estimate extracted | NR | No studies |
Hyperimmune immunoglobulin from human plasma vs saline placebo Quality of life · individuals with moderate or severe COVID‐19 Hyperimmune immunoglobulin for people with COVID‐19 (2023) · Cochrane | no estimate extracted | NR | No studies |
Early vs late tracheostomy Evidence from RCTs · hospitalized, mechanically ventilated adults with confirmed SARS‐CoV‐2 infection Early versus late tracheostomy in critically ill COVID‐19 patients (2023) · Cochrane | no estimate extracted | NR | No studies |
Early vs late tracheostomy Mortality · hospitalized, mechanically ventilated adults with confirmed SARS‐CoV‐2 infection Early versus late tracheostomy in critically ill COVID‐19 patients (2023) · Cochrane | no estimate extracted | NR | No studies |
Early vs late tracheostomy Need for renal replacement therapy · hospitalized, mechanically ventilated adults with confirmed SARS‐CoV‐2 infection Early versus late tracheostomy in critically ill COVID‐19 patients (2023) · Cochrane | no estimate extracted | NR | No studies |
Early vs late tracheostomy Evidence from NRSIs · hospitalized, mechanically ventilated adults with confirmed SARS‐CoV‐2 infection Early versus late tracheostomy in critically ill COVID‐19 patients (2023) · Cochrane | no estimate extracted | NR | No studies |
IV or oral iron alone vs no treatment Thromboembolic events5 (Subnet based on 50 studies including 15,408 participants) · patients at any age with solid cancer or haematological malignancy Intravenous iron versus oral iron versus no iron with or without erythropoiesis‐ stimulating agents (ESA)… (2022) · Cochrane | no estimate extracted | NR | No studies |
IV or oral iron alone vs no treatment Thrombocytopenia or haemorrhage5 (Subnet based on 13 studies including 2744 participants) · patients at any age with solid cancer or haematological malignancy Intravenous iron versus oral iron versus no iron with or without erythropoiesis‐ stimulating agents (ESA)… (2022) · Cochrane | no estimate extracted | NR | No studies |
IV or oral iron alone vs no treatment Hypertension5 (Subnet based on 24 studies including 8383 participants) · patients at any age with solid cancer or haematological malignancy Intravenous iron versus oral iron versus no iron with or without erythropoiesis‐ stimulating agents (ESA)… (2022) · Cochrane | no estimate extracted | NR | No studies |
ESA with or without iron vs no treatment Thrombocytopenia or haemorrhage5 (Subnet based on 13 studies including 2744 participants) · patients at any age with solid cancer or haematological malignancy Intravenous iron versus oral iron versus no iron with or without erythropoiesis‐ stimulating agents (ESA)… (2022) · Cochrane | no estimate extracted | NR | No studies |
ESA with or without iron vs no treatment Hypertension5 (Subnet based on 24 studies including 8383 participants) · patients at any age with solid cancer or haematological malignancy Intravenous iron versus oral iron versus no iron with or without erythropoiesis‐ stimulating agents (ESA)… (2022) · Cochrane | no estimate extracted | NR | No studies |
IV or oral iron alone vs no treatment Haemoglobin response (Subnet based on 31 studies including 6985 participants) · patients at any age with solid cancer or haematological malignancy Intravenous iron versus oral iron versus no iron with or without erythropoiesis‐ stimulating agents (ESA)… (2022) · Cochrane | no estimate extracted | NR | No studies |
Casirivimab/imdevimab vs placebo Admission to hospital within 6 months · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2 SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 (2022) · Cochrane | no estimate extracted | NR | No studies |
Casirivimab/imdevimab vs placebo Quality of life at longest · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2 SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 (2022) · Cochrane | no estimate extracted | NR | No studies |
Casirivimab/imdevimab vs placebo Adverse events: grade 1 to 2 · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2 SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 (2022) · Cochrane | no estimate extracted | NR | No studies |
Bamlanivimab vs placebo Outcomes · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2 SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 (2022) · Cochrane | no estimate extracted | NR | No studies |
Bamlanivimab vs placebo Development of clinical COVID‐19 symptoms within 30 days · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2 SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 (2022) · Cochrane | no estimate extracted | NR | No studies |
Bamlanivimab vs placebo Admission to hospital within 30 days · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2 SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 (2022) · Cochrane | no estimate extracted | NR | No studies |
Bamlanivimab vs placebo Quality of life at longest · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2 SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 (2022) · Cochrane | no estimate extracted | NR | No studies |
Bamlanivimab vs placebo Adverse events: grade 1 to 2 · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2 SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 (2022) · Cochrane | no estimate extracted | NR | No studies |
Bamlanivimab vs placebo Adverse events: grade 3 to 4 · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2 SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 (2022) · Cochrane | no estimate extracted | NR | No studies |